CO6300795A2 - Un vector adenovirico de simio para uso en una vacuna - Google Patents

Un vector adenovirico de simio para uso en una vacuna

Info

Publication number
CO6300795A2
CO6300795A2 CO10070274A CO10070274A CO6300795A2 CO 6300795 A2 CO6300795 A2 CO 6300795A2 CO 10070274 A CO10070274 A CO 10070274A CO 10070274 A CO10070274 A CO 10070274A CO 6300795 A2 CO6300795 A2 CO 6300795A2
Authority
CO
Colombia
Prior art keywords
viral vector
vector
adenoviric
simio
vaccine
Prior art date
Application number
CO10070274A
Other languages
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6300795(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6300795A2 publication Critical patent/CO6300795A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La invención se refiere a un vector adenovírico de simio deficiente de replicación C7 que codifica una proteína que comprende la proteína CS de P. falciparum o un fragmento de la misma, por ejemplo como se muestra en la SEC ID N° 1 o la SEC ID N° 3. La invención se refiere también a procedimientos de preparación de dicho vector vírico y al uso del vector vírico en el tratamiento/prevención de infección por malaria. Se describen también composiciones, vacunas y kits que comprenden dicho vector vírico. En un aspecto, la invención emplea un vector vírico C7 sintético. El vector vírico C7 según la invención puede coadministrarse o coformularse con un antígeno de la malaria tal como RTS,S, opcionalmente en presencia de un coadyuvante, por ejemplo, que comprende 3D-MPL y/o una saponina tal como QS21.
CO10070274A 2007-12-06 2010-06-10 Un vector adenovirico de simio para uso en una vacuna CO6300795A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06

Publications (1)

Publication Number Publication Date
CO6300795A2 true CO6300795A2 (es) 2011-07-21

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10070274A CO6300795A2 (es) 2007-12-06 2010-06-10 Un vector adenovirico de simio para uso en una vacuna

Country Status (20)

Country Link
EP (1) EP2227550A2 (es)
JP (1) JP2011505796A (es)
KR (1) KR20100108544A (es)
CN (1) CN101939438A (es)
AR (1) AR069568A1 (es)
AU (1) AU2008333208A1 (es)
BR (1) BRPI0819889A2 (es)
CA (1) CA2707245A1 (es)
CL (1) CL2008003614A1 (es)
CO (1) CO6300795A2 (es)
CR (1) CR11537A (es)
DO (1) DOP2010000164A (es)
IL (1) IL205953A0 (es)
MA (1) MA32003B1 (es)
MX (1) MX2010006207A (es)
PE (1) PE20091106A1 (es)
TW (1) TW200938633A (es)
UY (1) UY31510A1 (es)
WO (1) WO2009071613A2 (es)
ZA (1) ZA201003851B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
EP2694099B1 (en) * 2011-04-08 2019-10-16 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
PL376792A1 (pl) * 2002-10-23 2006-01-09 Glaxosmithkline Biologicals S.A. Sposoby szczepienia przeciwko malarii
EP1573012B1 (en) * 2002-12-17 2011-11-30 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
CA2553541C (en) * 2004-01-23 2015-04-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Chimpanzee adenovirus vaccine carriers
PT1802336E (pt) * 2004-10-14 2011-11-15 Glaxosmithkline Biolog Sa Vacinas de dose inicial/reforço para a malária
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
EP1998804B1 (en) * 2006-03-27 2014-04-16 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
AU2007276219B2 (en) * 2006-07-18 2013-10-03 Glaxosmithkline Biologicals S.A. Vaccines for malaria
EP2137210B1 (en) * 2007-03-02 2016-10-19 GlaxoSmithKline Biologicals SA Novel method and compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
CL2008003614A1 (es) 2010-01-15
AU2008333208A1 (en) 2009-06-11
DOP2010000164A (es) 2010-07-31
MA32003B1 (fr) 2011-01-03
WO2009071613A2 (en) 2009-06-11
MX2010006207A (es) 2010-10-04
UY31510A1 (es) 2009-08-03
EP2227550A2 (en) 2010-09-15
ZA201003851B (en) 2012-11-28
BRPI0819889A2 (pt) 2015-06-16
CN101939438A (zh) 2011-01-05
WO2009071613A3 (en) 2009-08-13
CA2707245A1 (en) 2009-06-11
TW200938633A (en) 2009-09-16
IL205953A0 (en) 2010-11-30
PE20091106A1 (es) 2009-08-24
JP2011505796A (ja) 2011-03-03
KR20100108544A (ko) 2010-10-07
AR069568A1 (es) 2010-02-03
CR11537A (es) 2010-08-18

Similar Documents

Publication Publication Date Title
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
EP4233898A3 (en) Influenza mrna vaccines
MX2022005291A (es) Vacunas para el tratamiento y prevencion del cancer.
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
MX347997B (es) Vacunas aviares vectorizadas con el virus de la enfermedad de newcastle.
PE20100658A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y UN ADYUVANTE QUE CONTIENE QS21, COLESTEROL Y 3D-MPL
DOP2011000389A (es) Antigenos rsv recombinantes
EA201070794A1 (ru) Рекомбинантные антигены rsv
MX340830B (es) Vacuna neumococica y usos de la misma.
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
AR061894A1 (es) Vacunas para malaria
WO2018193063A3 (en) NEW VACCINES AGAINST MALARIA AND ANTIBODIES BINDING PLASMODIUM SPOROZOIDS
BRPI1007721B1 (pt) composição de vacina para uso na indução de uma resposta imunológica contra um rotavírus em um indivíduo, cepa de rotavírus isolado de cdc-9 e cepa de rotavírus isolado de cdc-66
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
JP2014521605A5 (es)
CO2022003702A2 (es) Vacunas para vhb y métodos de tratamiento de vhb
CO6300795A2 (es) Un vector adenovirico de simio para uso en una vacuna
AR101814A1 (es) Partícula de tipo virus flavivirus
MX2016001695A (es) Composiciones inmunogenas de combinacion.
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
MX2019007924A (es) Vacunas contra la influenza.
UA102274C2 (ru) Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа

Legal Events

Date Code Title Description
FC Application refused